Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis-Reference-Cited by-同舟云学术

Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis

Published:2015-08-16 Issue:9 Volume:20 Page:639-645
ISSN:1320-5358
Container-title:Nephrology
language:en
Short-container-title:Nephrology

Author:

Yamada Shunsuke¹²,Tsuruya Kazuhiko¹³,Tokumoto Masanori²,Yoshida Hisako³,Ooboshi Hiroaki²,Kitazono Takanari¹

Affiliation:

1. Department of Medicine and Clinical Science; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

2. Department of Internal Medicine; Fukuoka Dental College; Fukuoka Japan

3. Department of Integrated Therapy for Chronic Kidney Disease; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

Publisher

Wiley

Subject

Nephrology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/nep.12509/fullpdf

Reference35 articles.

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD);Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group;Kidney Int. Suppl.,2009

2. Mineral metabolism and cardiovascular morbidity and mortality risk: Peritoneal dialysis patients compared with haemodialysis patients;Noordzji;Nephrol. Dial. Transplant.,2006

3. Cardiovascular risk factors in peritoneal dialysis patients revisited;Wang;Perit. Dial. Int.,2007

4. Alkaline phosphatase and mortality in patients on peritoneal dialysis;Liu;Clin. J. Am. Soc. Nephrol.,2014

5. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases;Ke;Endocr. Rev.,2012

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Only bioactive forms of PTH (n-oxPTH and Met18(ox)-PTH) inhibit synthesis of sclerostin – evidence from in vitro and human studies;Pflügers Archiv - European Journal of Physiology;2024-02-23

2. Evaluation of Renal Osteodystrophy and Serum Bone‐Related Biomarkers in a Peritoneal Dialysis Population;Journal of Bone and Mineral Research;2022-07-06

3. Bone Quality in CKD Patients: Current Concepts and Future Directions – Part I;Kidney Diseases;2021

4. Uremic Toxicity and Bone in CKD;Uremic Toxins and Organ Failure;2020

5. Sclerostin: a new biomarker of CKD–MBD;International Urology and Nephrology;2019-10-14